PMID- 23131589 OWN - NLM STAT- MEDLINE DCOM- 20130829 LR - 20161125 IS - 1638-6183 (Electronic) IS - 0300-9084 (Linking) VI - 95 IP - 4 DP - 2013 Apr TI - Expression and distribution of aggrecanases in human larynx: ADAMTS-5/aggrecanase-2 is the main aggrecanase in laryngeal carcinoma. PG - 725-34 LID - S0300-9084(12)00438-5 [pii] LID - 10.1016/j.biochi.2012.10.022 [doi] AB - Members of the ADAMTS family of proteases degrade proteoglycans and thereby have the potential to alter tissue architecture and regulate cellular functions. Aggrecanases are the main enzymes responsible for aggrecan degradation, due to their specific cleavage pattern. In this study, the expression status, the macromolecular organization and localization of ADAMTS-1, ADAMTS-4/aggrecanase-1 and ADAMTS-5/aggrecanase-2 in human normal larynx and laryngeal squamous cell carcinoma (LSCC) were investigated. On mRNA level, the results showed that ADAMTS-4 was the highest expressed enzyme in normal larynx, whereas ADAMTS-5 was the main aggrecanase in LSCC presenting a stage-related increase up to stage III (8-fold higher expression compared to normal), and thereafter decreased in stage IV. Accordingly, immunohistochemical analysis showed that ADAMTS-5, but not ADAMTS-4, was highly expressed by carcinoma cells. Sequential extraction revealed an altered distribution and organization of multiple molecular forms (latent, activated and fragmented forms) of the enzymes within the cancerous and their corresponding macroscopically normal laryngeal tissues, compared to the normal ones. Importantly, these analyses indicated that critical macromolecular changes occurred from the earliest LSCC stages not only in malignant parts of the tissue but also in areas that were not in proximity to carcinoma cells and appeared otherwise normal. Overall, the results of the present study show that ADAMTS-5/aggrecanase-2 is the main aggrecanase present in laryngeal carcinoma suggesting a critical role for the enzyme in aggrecan degradation and laryngeal tissue destruction during tumor progression. CI - Copyright (c) 2012 Elsevier Masson SAS. All rights reserved. FAU - Filou, S AU - Filou S AD - Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece. FAU - Stylianou, M AU - Stylianou M FAU - Triantaphyllidou, I E AU - Triantaphyllidou IE FAU - Papadas, T AU - Papadas T FAU - Mastronikolis, N S AU - Mastronikolis NS FAU - Goumas, P D AU - Goumas PD FAU - Papachristou, D J AU - Papachristou DJ FAU - Ravazoula, P AU - Ravazoula P FAU - Skandalis, S S AU - Skandalis SS FAU - Vynios, D H AU - Vynios DH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121103 PL - France TA - Biochimie JT - Biochimie JID - 1264604 RN - 0 (RNA, Messenger) RN - EC 3.4.24.- (ADAM Proteins) RN - EC 3.4.24.- (ADAMTS1 Protein) RN - EC 3.4.24.- (ADAMTS1 protein, human) RN - EC 3.4.24.- (ADAMTS5 Protein) RN - EC 3.4.24.- (ADAMTS5 protein, human) RN - EC 3.4.24.14 (Procollagen N-Endopeptidase) RN - EC 3.4.24.82 (ADAMTS4 Protein) RN - EC 3.4.24.82 (ADAMTS4 protein, human) SB - IM MH - ADAM Proteins/*genetics/*metabolism MH - ADAMTS1 Protein MH - ADAMTS4 Protein MH - ADAMTS5 Protein MH - Aged MH - Carcinoma, Squamous Cell/enzymology/genetics/metabolism MH - Female MH - *Gene Expression Regulation, Neoplastic MH - Humans MH - Laryngeal Neoplasms/*enzymology/*genetics/metabolism MH - Larynx/enzymology/*metabolism MH - Male MH - Procollagen N-Endopeptidase/genetics/metabolism MH - Protein Transport MH - RNA, Messenger/genetics/metabolism EDAT- 2012/11/08 06:00 MHDA- 2013/08/30 06:00 CRDT- 2012/11/08 06:00 PHST- 2012/06/05 00:00 [received] PHST- 2012/10/27 00:00 [accepted] PHST- 2012/11/08 06:00 [entrez] PHST- 2012/11/08 06:00 [pubmed] PHST- 2013/08/30 06:00 [medline] AID - S0300-9084(12)00438-5 [pii] AID - 10.1016/j.biochi.2012.10.022 [doi] PST - ppublish SO - Biochimie. 2013 Apr;95(4):725-34. doi: 10.1016/j.biochi.2012.10.022. Epub 2012 Nov 3.